共 50 条
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study
被引:32
|作者:
Moghaddam, Bahar
[1
]
Marozoff, Shelby
[2
]
Li, Lingyi
[2
,3
]
Sayre, Eric C.
[2
]
Antonio Avina-Zubieta, J.
[2
,3
,4
]
机构:
[1] Icahn Sch Med Mt Sinai, Div Rheumatol, Dept Med, New York, NY 10029 USA
[2] Arthrit Res Canada, 230-2238 Yukon St, Vancouver, BC V5Y 3P2, Canada
[3] Univ British Columbia, Expt Med Program, Dept Med, Vancouver, BC, Canada
[4] Univ British Columbia, Div Rheumatol, Dept Med, Vancouver, BC, Canada
来源:
基金:
加拿大健康研究院;
关键词:
Key words;
systemic lupus erythematosus;
epidemiology;
mortality;
cancer;
risk;
cohort;
MYOCARDIAL-INFARCTION;
RHEUMATOID-ARTHRITIS;
RISK;
CANCER;
GRANULOMATOSIS;
POLYANGIITIS;
DIAGNOSES;
DISEASE;
STROKE;
TRENDS;
D O I:
10.1093/rheumatology/keab362
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective To investigate all-cause and cause-specific mortality in SLE patients between two time periods, 1997-2005 and 2006-14. Methods We used an administrative health database from the province of British Columbia, Canada to match all incident SLE patients to 10 non-SLE individuals on sex, age and index date. Cohorts were divided into two subgroups, according to diagnosis year: early cohort 1997-2005 and late cohort 2006-14. The outcome was death [all-cause, renal disease, cancer, infection, cardiovascular disease (CVD) and other]. Hazard ratios (HR) and 95% CIs were estimated using univariate and multivariable Cox models. Results Among 6092 SLE patients and 60 920 non-SLE individuals, there were 451 and 1910 deaths, respectively. The fully adjusted all-cause mortality HR (95% CI) in the overall SLE cohort was 1.85 (1.66, 2.06), with no statistically significant improvement between early and late cohorts [1.95 (1.69, 2.26) vs 1.74 (1.49, 2.04)]. There was excess mortality from renal disease [3.04 (2.29, 4.05)], infections [2.74 (2.19, 3.43)] and CVD [2.05 (1.77, 2.38)], but not cancer [1.18 (0.96, 1.46)], in the overall SLE cohort. There was no statistically significant improvement in cause-specific mortality between early and late cohorts for renal disease [3.57 (2.37, 5.36) vs 2.65 (1.78, 3.93)], infection [2.94 (2.17, 3.98) vs 2.54 (1.84, 3.51)] and CVD [1.95 (1.60, 2.38) vs 2.18 (1.76, 2.71)]. There was no increase in cancer-related mortality in either cohort [1.27 (0.96, 1.69) vs 1.10 (0.82, 1.48)]. Conclusion This population-based study demonstrates a persisting mortality gap in all-cause and cause-specific deaths in SLE patients, compared with the general population.
引用
收藏
页码:367 / 376
页数:10
相关论文